SWOG clinical trial number
SWOG-9338

A Phase II Trial of Combination Therapy With 5-Fluorouracil, a-Interferon and Interleukin-2 ("FUNIL") for Advanced Renal Cell Carcinoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Advanced Renal
Activated
12/15/1994
Closed
09/01/1997

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2000

Infusional interleukin-2 and 5-fluorouracil with subcutaneous intergeron-a for the treatment of patients with advanced renal cell carcinoma: A Southwest Oncology Group phase ll study.

L Elias;D Lew;RA Figlin;RC Flanigan;ME Thompson;PL Triozzi;RJ Belt;DP Wood;SE Rivkin;ED Crawford Cancer 89(3):597-603

1999

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-a for advanced renal cell carcinoma. A Southwest Oncology Group study.

L Elias;D Lew;RA Figlin;RC Flanigan;ME Thompson;PL Triozzi;RJ Belt;DP Wood;SE Rivkin;ED Crawford Proc of the American Society of Clinical Oncology 18:331a(#1275)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase